


GLP-1 based Peptides – Analysis by NMR Spectroscopy



Semaglutide

Tirzepatide

Liraglutide

Dulaglutide

GLP-1-based peptide therapeutics in diabetes and obesity treatment brings enormous promise - but also growing regulatory pressure. If you are a peptide manufacturer, you need clear answers to three questions:

- ➔ ... is the structure correct?
- ➔ ... is the batch consistent?
- ➔ ... is the content precise?

High-field NMR spectroscopy provides these answers-accurately, quickly, and regulator-ready.

We analyse your peptide drug substance or finished product using **high-resolution NMR**, meeting **FDA, EMA**, and **ICH** standards.



We Deliver:

- ➔ **Peptide identity confirmation**
(primary structure, sequence verification)
- ➔ **Batch-to-batch comparison**
(for process validation, comparability or biosimilars)
- ➔ **Secondary structure analysis**
(folding, rigidity, higher-order structure)
- ➔ **Content determination** (qNMR for purity and assay)

Why Top Manufacturers Choose Spectral Service?

- ✓ Regulatory-grade data – Ready for FDA, EMA, ICH submissions
 - ✓ Proven for complex peptides – Long, modified, or novel structures
 - ✓ Short lead times – From sample receipt to report in 10 days for routine analysis
 - ✓ Trusted by industry leaders – Serving pharma, biotech and more
-
- ✓ Ready to Analyze your Diabetes Peptide Product or another Peptide?